Cullinan Oncology, Inc. (CGEM)
Automate Your Wheel Strategy on CGEM
With Tiblio's Option Bot, you can configure your own wheel strategy including CGEM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CGEM
- Rev/Share 0.0
- Book/Share 9.3683
- PB 0.9265
- Debt/Equity 0.0033
- CurrentRatio 11.6191
- ROIC -0.3767
- MktCap 512247596.0
- FreeCF/Share -2.5501
- PFCF -3.4102
- PE -2.8606
- Debt/Assets 0.0032
- DivYield 0
- ROE -0.2947
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass. and TOKYO, Japan and PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), Taiho Pharmaceutical Co., Ltd., and Taiho Oncology, Inc. today announced new positive results from the pivotal Phase 2b cohorts of the REZILIENT1 trial, a Phase 1/2 clinical trial of zipalertinib monotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) who have received prior therapy. These data will be presented on Sunday, June 1 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting as an oral …
Read More
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025
Read More
Wall Street Analysts Predict a 292.51% Upside in Cullinan Therapeutics (CGEM): Here's What You Should Know
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Cullinan Therapeutics (CGEM) points to a 292.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Initial clinical data from global Phase 1 study of CLN-978 in Systemic Lupus Erythematosus (SLE) expected in Q4 2025; CLN-978 remains the first and only development-stage CD19 T cell engager in an autoimmune disease clinical trial in the U.S. Zipalertinib pivotal Phase 2b study met primary endpoint; full results mid-year 2025 and NDA submission planned H2 2025, pending regulatory discussions Cash and investments of $606.9 million as of December 31, 2024, continues to provide runway into 2028 CAMBRIDGE, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, …
Read More
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced its participation in the following upcoming investor conferences: Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D.
Read More
About Cullinan Oncology, Inc. (CGEM)
- IPO Date 2021-01-08
- Website https://www.cullinanoncology.com
- Industry Biotechnology
- CEO Mr. Nadim Ahmed
- Employees 111